Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Haini Wen, Lin Yin, Jiangrong Wang, Lin Zhang, Tao Sun, Feng Xu, Minxin Zhang, Li Liu, Renfang Zhang, Xiaoqian Liu, Xianmin Meng, Yaru Xing, Hongzhou Lu, Zheng Jiao & Lijun Zhang. (2022) Population pharmacokinetics and model-informed precision dosing of lamivudine in Chinese HIV-infected patients with mild and moderate impaired renal function. Expert Review of Clinical Pharmacology 15:5, pages 647-655.
Read now
Read now
Piyanuch Wonganan, Wacharee Limpanasithikul, Suree Jianmongkol, Stephen J. Kerr & Kiat Ruxrungtham. (2020) Pharmacokinetics of nucleoside/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection. Expert Opinion on Drug Metabolism & Toxicology 16:7, pages 551-564.
Read now
Read now
Arturo Ciccullo, Gianmaria Baldin, Alberto Borghetti & Simona Di Giambenedetto. (2020) Dolutegravir plus lamivudine for the treatment of HIV-1 infection. Expert Review of Anti-infective Therapy 18:4, pages 279-292.
Read now
Read now
Dario Cattaneo, Amedeo Capetti & Giuliano Rizzardini. (2019) Drug–drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment. Expert Opinion on Drug Metabolism & Toxicology 15:3, pages 245-252.
Read now
Read now
Seyeon Kim & Joon Hee Hong. (2015) Synthesis and Anti-HIV Activity of Novel 2′-Deoxy-2′-β-Fluoro-Threosyl Nucleoside Phosphonic Acid Analogues. Nucleosides, Nucleotides & Nucleic Acids 34:12, pages 815-833.
Read now
Read now
José Luis Casado & Sara Bañón. (2015) Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection. Expert Review of Clinical Pharmacology 8:6, pages 709-718.
Read now
Read now
Pauline Bollen, Peter Reiss, Jonathan Schapiro & David Burger. (2015) Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection. Expert Opinion on Drug Safety 14:9, pages 1457-1472.
Read now
Read now
Marta Florit-Sureda, Maria Giner-Soriano, Javier Mateu-de Antonio & Alexia Carmona-Yelo. (2014) Effective treatment of a highly active antiretroviral regimen through jejunostomy. Journal of Chemotherapy 26:3, pages 176-179.
Read now
Read now
Christopher A Koczor & William Lewis. (2010) Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA. Expert Opinion on Drug Metabolism & Toxicology 6:12, pages 1493-1504.
Read now
Read now
Articles from other publishers (17)
Andrea Angeli. 2024. Metalloenzymes. Metalloenzymes
23
34
.
Lei Huang, Jing Lei, Yuanxun Yang, Tingting Ma, Hui Lin, Bei Cao & Juan Li. (2023) Pharmacokinetic and Bioequivalence Evaluation of Single‐Tablet and Separate‐Tablet Regimens for Ainuovirine, Lamivudine, and Tenofovir Disoproxil Fumarate in Chinese Healthy Subjects. Clinical Pharmacology in Drug Development.
Crossref
Crossref
Franck Amblard, Dharmeshkumar Patel, Eleftherios Michailidis, Steven J. Coats, Mahesh Kasthuri, Nicolas Biteau, Zahira Tber, Maryam Ehteshami & Raymond F. Schinazi. (2022) HIV nucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry 240, pages 114554.
Crossref
Crossref
Angélica Saraí Jiménez-Osorio, Sinaí Jaen-Vega, Eduardo Fernández-Martínez, María Araceli Ortíz-Rodríguez, María Fernanda Martínez-Salazar, Reyna Cristina Jiménez-Sánchez, Olga Rocío Flores-Chávez, Esther Ramírez-Moreno, José Arias-Rico, Felipe Arteaga-García & Diego Estrada-Luna. (2022) Antiretroviral Therapy-Induced Dysregulation of Gene Expression and Lipid Metabolism in HIV+ Patients: Beneficial Role of Antioxidant Phytochemicals. International Journal of Molecular Sciences 23:10, pages 5592.
Crossref
Crossref
Rickesh Patel, Lee Evitt, Ilias Mariolis, Simona Di Giambenedetto, Antonella d’Arminio Monforte, José Casado, Alfonso Cabello Úbeda, Laurent Hocqueloux, Clotilde Allavena, Tristan Barber, Diwakar Jha, Rahul Kumar, Rahul Dinesh Kamath, Tia Vincent, Jean van Wyk & Justin Koteff. (2021) HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review. Infectious Diseases and Therapy 10:4, pages 2051-2070.
Crossref
Crossref
Leonardo Calza, Vincenzo Colangeli, Marco Borderi, Diletta Testi, Bianca Granozzi, Isabella Bon, Maria Carla Re & Pierluigi Viale. (2020) Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy. Journal of Antimicrobial Chemotherapy 75:11, pages 3327-3333.
Crossref
Crossref
Tyler A. Shaw, Christopher J. Ablenas, Geneviève F. Desrochers, Megan H. Powdrill, Didier A. Bilodeau, Jean-François Vincent-Rocan, Meijuan Niu, Anne Monette, Andrew J. Mouland, André M. Beauchemin & John Paul Pezacki. (2020) A Bifunctional Nucleoside Probe for the Inhibition of the Human Immunodeficiency Virus-Type 1 Reverse Transcriptase. Bioconjugate Chemistry 31:5, pages 1537-1544.
Crossref
Crossref
Teodora Pene Dumitrescu, Kavita Peddiraju, Caifeng Fu, Kalpana Bakshi, Shui Yu, Zhiping Zhang, Allan R. Tenorio, Chris Spancake, Shashidhar Joshi, Allen Wolstenholme & Kimberly Adkison. (2019) Bioequivalence and Food Effect Assessment of 2 Fixed‐Dose Combination Formulations of Dolutegravir and Lamivudine. Clinical Pharmacology in Drug Development 9:2, pages 189-202.
Crossref
Crossref
Xuwang Chen, Fanlong Bu, Rong Li, Guiyan Yuan, Yanyan Wang & Benjie Wang. (2019) Overview of the Chromatographic and Mass Spectrometry Analytical Methods for Determination of Lamivudine in Biological Fluids. Current Pharmaceutical Analysis 15:2, pages 103-108.
Crossref
Crossref
Romina Quercia, Carlo-Federico Perno, Justin Koteff, Katy Moore, Cynthia McCoig, Marty St. Clair & Daniel Kuritzkes. (2018) Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes 78:2, pages 125-135.
Crossref
Crossref
José A Perez-Molina, Rafael Rubio, Antonio Rivero, Juan Pasquau, Ignacio Suárez-Lozano, Melcior Riera, Miriam Estébanez, Jesús Santos, José Sanz-Moreno, Jesús Troya, Ana Mariño, Antonio Antela, Jordi Navarro, Herminia Esteban & Santiago Moreno. (2015) Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. The Lancet Infectious Diseases 15:7, pages 775-784.
Crossref
Crossref
Seyeon Kim, Jun-Pil Jee & Joon Hee Hong. (2015) Design and Synthesis of Novel 2'(β)-Fluoro-3'(α)-hydroxy-threose Nucleosides: Iso-FMAU Analogues as Potent Antiviral Agents. Journal of the Chosun Natural Science 8:2, pages 99-106.
Crossref
Crossref
Joon Hee Hong. (2015) Synthesis of Novel 2'(β)-Methyl-5'-deoxyapiose Nucleoside Phosphonic Acid Analogues as Antiviral Agents. Journal of the Chosun Natural Science 8:1, pages 48-55.
Crossref
Crossref
Chiara Piana, Wei Zhao, Kimberly Adkison, David Burger, Evelyne Jacqz-Aigrain, Meindert Danhof & Oscar Della Pasqua. (2014) Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children. British Journal of Clinical Pharmacology 77:5, pages 861-872.
Crossref
Crossref
María José Abad Martínez, Luis Miguel Bedoya del Olmo & Paulina Bermejo Benito. 2014.
197
221
.
N. Jung, C. Lehmann, A. Rubbert, E. Schömig, G. Fätkenheuer, P. Hartmann & D. Taubert. (2012) Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients. Infection 41:2, pages 379-385.
Crossref
Crossref
Sihem Benaboud, Jean Marc Tréluyer, Saik Urien, Stéphane Blanche, Naim Bouazza, Hélène Chappuy, Elisabeth Rey, Emmanuelle Pannier, Ghislaine Firtion, Odile Launay & Déborah Hirt. (2012) Pregnancy-Related Effects on Lamivudine Pharmacokinetics in a Population Study with 228 Women. Antimicrobial Agents and Chemotherapy 56:2, pages 776-782.
Crossref
Crossref